Concepedia

Valentina Molteni

VM

37

Publications

2.9K

Citations

27

H-Index

1995

Active since

Affiliations

Genomics Institute of the Novartis Research Foundation(Current)

Novartis (United States)

University of California San Diego

University of Milan

Novartis (Switzerland)

Valentina Molteni is an author at Genomics Institute of the Novartis Research Foundation specializing in medicine, pharmacology, and drug discovery.

Top concepts

MedicinePharmacologyDrug DiscoveryNatural SciencesOrganic ChemistryChemistryEngineeringBiomolecular EngineeringMedicinal ChemistryBiochemistry

Publications per year

1995–2020

37

Publications

37

The nuclear receptor LXR is a glucose sensor

Nico Mitro, Puiying A. Mak, Leo Vargas et al. · Nature · 2006 · 512 citations

Nuclear Receptor Lxr, Signal Transduction, G Protein-coupled Receptor +3

Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness

Shilpi Khare, A. S. Nagle, Agnes Biggart et al. · Nature · 2016 · 407 citations · Full text

Proteasome Inhibition, Medicinal Chemistry, Antiparasitic Agent +11

Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)

David C. Tully, Paul V. Rucker, D. CHIANELLI et al. · Journal of Medicinal Chemistry · 2017 · 224 citations · Full text

Pathology, Farnesoid X Receptor, Pharmacotherapy +20

One-Pot Electrochemical Nickel-Catalyzed Decarboxylative Sp<sup>2</sup>–Sp<sup>3</sup> Cross-Coupling

Takaoki Koyanagi, Ananda Herath, Ashley Chong et al. · Organic Letters · 2019 · 113 citations

Discovery and Characterization of Clinical Candidate LXE408 as a Kinetoplastid-Selective Proteasome Inhibitor for the Treatment of Leishmaniases

A. S. Nagle, Agnes Biggart, C. Be et al. · Journal of Medicinal Chemistry · 2020 · 111 citations · Full text

Rows per page

1–5 of 37